Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study

American Heart Journal

Volumn 167, Issue 5, 2014, Pages

  Daniels, Lori B ^a,b   Clopton, Paul ^a,c   Laughlin, Gail A ^b   Maisel, Alan S ^a,c   Barrett Connor, Elizabeth ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMMUNITY; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALIFORNIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HUMANS; INFORMED CONSENT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84899548228     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.12.031     Document Type: Article

References (26)

1. U.C. Sharma, S. Pokharel, and T.J. van Brakel et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 19 2004 3121 3128
2. V.L. Thijssen, S. Hulsmans, and A.W. Griffioen The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells Am J Pathol 172 2 2008 545 553
3. M. Papaspyridonos, E. McNeill, and J.P. de Bono et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction Arterioscler Thromb Vasc Biol 28 3 2008 433 440
4. L. Calvier, M. Miana, and P. Reboul et al. Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler Thromb Vasc Biol 33 1 2013 67 75
5. R.R. van Kimmenade, J.L. Januzzi Jr., and P.T. Ellinor et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 6 2006 1217 1224
6. R.A. de Boer, D.J. Lok, and T. Jaarsma et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 1 2011 60 68
7. D.J. Lok, P. Van Der Meer, and P.W. de la Porte et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 5 2010 323 328
8. R.V. Shah, A.A. Chen-Tournoux, and M.H. Picard et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 8 2010 826 832
9. G.M. Felker, M. Fiuzat, and L.K. Shaw et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ Heart Fail 5 1 2012 72 78
10. E.W. Grandin, P. Jarolim, and S.A. Murphy et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 Clin Chem 58 1 2012 267 273
11. R.A. de Boer, D.J. van Veldhuisen, and R.T. Gansevoort et al. The fibrosis marker galectin-3 and outcome in the general population J Intern Med 272 1 2012 55 64
12. J.E. Ho, C. Liu, and A. Lyass et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 14 2012 1249 1256
13. A.S. Levey, L.A. Stevens, and C.H. Schmid et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
14. Diabetes Drafting Group Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group Diabetologia 28 Suppl 1985 615 640
15. D.D. Reid, P.J. Hamilton, and P. McCartney et al. Smoking and other risk factors for coronary heart-disease in British civil servants Lancet 2 7993 1976 979 984
16. L.B. Daniels, E. Barrett-Connor, and P. Clopton et al. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study J Am Coll Cardiol 59 12 2012 1101 1109
17. W.K. Kremers Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time 2007 Mayo Clinic Rochester, MN
18. S. May, and D.W. Hosmer A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model Lifetime Data Anal 4 2 1998 109 120
19. M.J. Pencina, R.B. D'Agostino Sr., and R.B. D'Agostino Jr. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2 2008 157 172 discussion 207-12
20. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 1 2011 11 21
21. M.J. Pencina, R.B. D'Agostino, and R.S. Vasan Statistical methods for assessment of added usefulness of new biomarkers Clin Chem Lab Med 48 12 2010 1703 1711
22. Y.H. Liu, M. D'Ambrosio, and T.D. Liao et al. N-acetyl-seryl-aspartyl- lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Am J Physiol Heart Circ Physiol 296 2 2009 H404 H412
23. A.R. Van der Velde, L. Gullestad, and T. Ueland et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH Circ Heart Fail 6 2 2013 219 226
24. H. Milting, P. Ellinghaus, and M. Seewald et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices J Heart Lung Transplant 27 6 2008 589 596
25. V.V. Glinsky, and A. Raz Modified citrus pectin anti-metastatic properties: one bullet, multiple targets Carbohydr Res 344 14 2009 1788 1791
26. R.H. Christenson, S.H. Duh, and A.H. Wu et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure Clin Biochem 43 7-8 2010 683 690